Verve Therapeutics reports voting results from annual meeting

Verve Therapeutics, Inc. (Market cap: $573.19M), a biotechnology company specializing in pharmaceutical preparations, disclosed the outcomes of its recent Annual Meeting of Stockholders in an 8-K filing with the U.S. Securities and Exchange Commission. According to InvestingPro data, the company maintains a strong financial health score, with more cash than debt on its balance sheet. The meeting took place on June 5, 2025, where stockholders voted on several key proposals.

In the first proposal, stockholders elected three Class I directors to the company’s board. Lonnel Coats, Jodie Morrison, and Krishna Yeshwant, M.D., will serve a three-year term ending at the 2028 annual meeting. The voting results were as follows: Coats received 58,699,561 votes for and 686,894 withheld, Morrison had 58,628,402 votes for and 758,053 withheld, and Yeshwant received 50,208,438 votes for with 9,178,017 withheld. There were 13,681,266 broker non-votes for each candidate.

The second proposal concerned the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal was approved with 72,754,346 votes for, 75,512 against, and 237,863 abstaining.

The third proposal was an advisory vote on the compensation of the company’s named executive officers. The compensation was approved with 56,159,136 votes for, 2,748,937 against, and 478,381 abstaining. There were also 13,681,266 broker non-votes for this proposal.

No other matters were submitted to a vote at the Annual Meeting. The 8-K filing, signed by Chief Financial Officer Allison Dorval, confirms that all information is based on the official SEC filing. Recent InvestingPro analysis shows the stock has delivered a significant 26% return over the past week, with analysts setting price targets ranging from $15 to $39. For deeper insights into Verve Therapeutics’ financial health and growth prospects, including 8 additional ProTips and comprehensive valuation metrics, explore the detailed Pro Research Report available on InvestingPro.

In other recent news, Verve Therapeutics has reported its first-quarter earnings for 2025, alongside promising interim data from its VERVE-101 Phase 1b Heart-2 trial. The results highlighted positive safety and efficacy outcomes, with further data expected later in the year. Canaccord Genuity maintained its Buy rating and increased its price target to $39, reflecting confidence in Verve’s clinical progress. Similarly, BMO Capital Markets reiterated an Outperform rating with a $30 price target, citing the promising results from Verve’s lipid nanoparticle technology and its potential impact on LDL cholesterol reduction. Guggenheim also raised its price target to $24, following encouraging data from the VERVE-102 trial that demonstrated a significant reduction in LDL levels.

The analyst firm noted the absence of serious adverse events and a consistent reduction in LDL cholesterol across various dosing cohorts. William Blair maintained an Outperform rating, emphasizing the favorable comparison of VERVE-102’s efficacy and safety profile against competing treatments. Verve Therapeutics continues to engage with investors, offering insights into their clinical trials and future plans. The company is poised for several key milestones, including potential collaboration opportunities with Eli Lilly (NYSE:LLY) by the end of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.